证券代码：600587 证券简称：新华医疗 公告编号：临 2025-029 山东新华医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近日 收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况 如下： 一、医疗器械注册证的具体情况 1、产品名称：全自动软式内镜清洗消毒器 2、注册证编号：鲁械注准 20252110285 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所： 山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博市周村区新华大道 2009 号 6、结构及组成：由洗消槽、密封门、管路系统、外装饰罩及控制系统组成 8、适用范围：用于对软式内镜的清洗消毒 9、批准日期：2025 年 05 月 26 日 10、有效期至：2030 年 05 月 25 日 11、同类产品相关情况：根据国家药品监督管理局官网数据查询信息，截至目 前，国内同行业有 30 家公 ...

Core Viewpoint - Xinhua Medical (600587) is actively expanding its product offerings in logistics and medical equipment, demonstrating a commitment to innovation and market penetration in the healthcare sector [2][3]. Group 1: Company Performance - As of June 4, 2025, Xinhua Medical's stock closed at 15.58 yuan, down 0.7%, with a turnover rate of 1.37% and a trading volume of 82,900 shares, amounting to a transaction value of 129 million yuan [1]. - On June 4, 2025, the net inflow of funds showed a positive trend with main funds net inflow of 13.58 million yuan and speculative funds net inflow of 11.51 million yuan, while retail investors experienced a net outflow of 25.08 million yuan [3][4]. Group 2: Product Development - Xinhua Medical has developed various logistics robots, including hospital logistics robots, high-value consumables logistics robots, cleaning logistics robots, sterilization logistics robots, low-temperature logistics robots, and stacking robots, aimed at enhancing smart logistics management in healthcare [2]. - The company has successfully bid for the Guizhou Province centralized procurement project for high-end radiotherapy equipment, marking a significant breakthrough for domestic high-end medical devices in grassroots healthcare markets [2]. Group 3: Corporate Governance - The 2024 Annual General Meeting held on June 3, 2025, approved multiple resolutions, including the annual report, financial statements, and profit distribution plan, with all resolutions receiving majority support [4][5]. - The company is committed to enhancing shareholder value through various measures, including stock buybacks, high dividend payouts, and management's potential share purchases, while emphasizing that stock price fluctuations are influenced by multiple external factors [3][5].

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-028 山东新华医疗器械股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 06 月 03 日 (二)股东大会召开的地点：淄博市高新技术产业开发区泰美路 7 号新华医疗科技 园办公楼三楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 400 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 205,817,391 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的 | | | 比例（%） | 33.9253 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长王玉全先生主持，会议采用现场投 票与网络投票相结合的方式表决，符合《公 ...

票结果均由上海证券交易所交易系统和互联网投票系统予以认证。 北 京 市 东 城 区 北 三 环 东 路 36 号环球 贸易中心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 北京市君致律师事务所 关于山东新华医疗器械股份有限公司 2024 年年度股东大会的法律意见书 致：山东新华医疗器械股份有限公司 北京市君致律师事务所（以下简称"本所"）受山东新华医疗器械股份有限公 司（以下简称"公司"）的委托，指派律师出席 2025 年 6 月 3 日上午 9:00 点召开 的公司 2024 年年度股东大会（以下简称"本次股东大会"）；依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）等现行法律、 法规和其他规范性文件及《山东新华医疗器械股份有限公司章程》的规定，特就 公司本次股东大会相关事宜，出具本法律意见书。 对本法律意见书的出具，本所特作如下声明： 1、本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则》等 ...

Group 1 - The stock price of Xinhua Medical (600587) closed at 15.54 yuan on May 30, 2025, with a slight increase of 0.13% and a turnover rate of 0.97% [1] - On the same day, the net outflow of main funds was 614.75 million yuan, while retail investors saw a net inflow of 500.33 million yuan [2][3] - The controlling shareholder, Shandong Yiyang Health Industry Development Group, plans to increase its stake in Xinhua Medical by investing between 100 million yuan and 200 million yuan over the next 12 months, supported by a loan commitment of up to 180 million yuan from the Bank of China [2][3]

Group 1 - The core point of the announcement is that the controlling shareholder, Shandong Yiyang Health Industry Development Group Co., Ltd., plans to increase its stake in Xinhua Medical through a loan commitment from Industrial and Commercial Bank of China, Shandong Branch, amounting to no more than RMB 180 million [1][2] - The increase plan is based on the confidence in Xinhua Medical's future stable development and long-term investment value, with a planned investment amount between RMB 100 million and RMB 200 million within 12 months starting from May 27, 2025 [1] - The loan commitment from the bank is specifically for the purpose of supporting the increase in A-share stock, with a loan term not exceeding 3 years [2]

详见公司于2025年5月27日在上海证券交易所网站（www.sse.com.cn）披露 的《新华医疗关于公司控股股东增持公司股份计划的公告》（公告编号：临 2025-026）。 二、贷款承诺函的主要内容 工商银行山东省分行已为山东健康集团出具《上市公司股票增持贷款承诺 函》，同意为山东健康集团增持公司A股股票提供专项贷款支持，贷款金额不超 过人民币18,000万元，贷款期限不超过3年。 证券代码：600587 证券简称：新华医疗 公告编号：临 2025-027 山东新华医疗器械股份有限公司 关于控股股东取得增持股份专项贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）收到 控股股东山东颐养健康产业发展集团有限公司（以下简称"山东健康集团"）通 知，山东健康集团已获得中国工商银行股份有限公司山东省分行（以下简称"工 商银行山东省分行"）出具的《上市公司股票增持贷款承诺函》。工商银行山东 省分行拟为山东健康集团增持公司股份计划提供不超过人民币18, ...

Industry Overview - The dental medical equipment industry is experiencing rapid growth in China, driven by an aging population and increasing disposable income, leading to heightened awareness of oral health [1][8] - The market size for dental medical equipment in China is projected to grow from 22.3 billion yuan in 2020 to 41.2 billion yuan in 2024, with a compound annual growth rate (CAGR) of 16.59% [1][8] - The global dental medical equipment market is also expanding, expected to increase from 14.6 billion USD in 2020 to 20.7 billion USD in 2024, with a CAGR of 9.12% [6] Market Dynamics - The demand for dental medical services is rising, leading to a robust growth phase for the dental equipment market in China [1][8] - The domestic market for dental medical equipment is forecasted to reach 47.9 billion yuan by 2025 [1][8] - The domestic CBCT (Cone Beam Computed Tomography) market is becoming a focal point, with the localization rate expected to rise from 16.3% in 2020 to 56.44% in 2024 [10][18] Competitive Landscape - Major players in the Chinese dental medical equipment market include Xinhua Medical, Meiya Optoelectronics, Times Angel, and Kangzhong Medical [2][12] - The industry is currently reliant on imports for 90% of its dental equipment, particularly in the mid-to-high-end segments, but there is a significant opportunity for domestic companies to replace imports [12][18] - Key products from leading companies include CBCT systems, dental sterilization equipment, and implant devices [14][16] Development Trends - There is a notable acceleration in domestic replacement and technological breakthroughs, particularly in CBCT, with expectations for further advancements in high-end sectors [18] - The integration of digital and intelligent technologies is transforming the dental medical equipment industry, enhancing diagnostic efficiency and patient experience [19] - The market is witnessing a segmentation in demand, with older populations driving the need for dental implants and younger consumers pushing for aesthetic treatments like invisible orthodontics [20]

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

Group 1 - The controlling shareholder of Shandong Xinhua Medical Instrument Co., Ltd. plans to increase its stake in the company, currently holding 175,385,227 shares, which accounts for 28.91% of the total share capital of 606,677,919 shares [2][3] - The increase plan aims to invest no less than RMB 100 million and no more than RMB 200 million within 12 months through the Shanghai Stock Exchange [2][3] - If the shareholding ratio reaches or exceeds 30%, the controlling shareholder will apply to the China Securities Regulatory Commission for exemption from making a tender offer [2][4] Group 2 - A subsidiary of the company has received a Class III medical device registration certificate for a dialysis fluid filter, which is designed to remove endotoxins, bacteria, and insoluble particles from dialysis fluid [7][8] - The product has a filtration rate of ≥1000 ml/min and meets strict microbial and endotoxin removal standards, enhancing the safety and quality of dialysis treatment [9] - The introduction of this product enriches the company's blood purification product line, potentially improving its core competitiveness in the market [9]